Media & Investors

We’re committed to transparency – access our key documents and share price, all in one place.

Image

Investor Overview

Growing with Kuros

  • Extremities volume growth and sales performance on target
  • Launch of MagnetOs MIS (Minimally Invasive Surgery) delivery system
  • First time operating profit of USD 3.5mn

  • Direct sales increased 77% year-over-year
  • Total revenue reached USD 63.5mn in H1/2025

  • Healthy profitability with adjusted group EBITDA margin of 12.3%
  • Robust cash position of USD 18.4mn

Financial Data

Kuros Biosciences is fully committed to good corporate governance and adherence to high ethical standards. Our principles and rules on corporate governance and ethical conduct are articulated in the Articles of Association, the Internal Regulations, the charters of the committees of our board of directors, and our code of conduct.

Annual Reports

Interim Results

Presentations

Shareholder Meetings

Minutes of the AGM – English, 15 April 2025
Minutes of the AGM – German, 15 April 2025
U.S. Stock Option and Equity Incentive Plan Regulation 2025
Striving for Accessibility

Striving for sustainability

Our commitment to people & planet

Kuros is deeply committed to a sustainable future for all.

Today, Environmental, Social, and Governance (ESG) principles are increasingly guiding how we operate — from sustainable manufacturing to community engagement.

While we are in the early stages of formalizing our ESG framework, we are actively evaluating and implementing strategies to align our operations with these principles.